CNS Drugs

, Volume 17, Issue 5, pp 293–305 | Cite as

Transient Ischaemic Attacks

New Approaches to Management
Therapy In Practice


The fact that transient ischaemic attacks are a harbinger for the possible development of ischaemic stroke has been recognised for several decades. However, within the past decade, our concepts regarding transient ischaemic attacks as a distinct entity from stroke and the prognosis for transient ischaemic attack patients have been challenged. In addition, clinical trials have clarified that modem transient ischaemic attack management is more complex than in the past, with the addition of newer pharmacological options to the stroke prevention armamentarium.

Recent information regarding newer antiplatelet agents is reviewed in this article, along with results of clinical trials pertaining to warfarin in stroke prevention. The evolving role of statins, ACE inhibitors and estrogen replacement is reviewed. Finally, the appropriate use of surgery following transient ischaemic ttacks is outlined. Recent studies have shown that many patients will benefit from a multimodal pharmacological approach following transient cerebral ischaemia, and the potential for combination therapy is highlighted.


Warfarin Ischaemic Stroke Clopidogrel Ticlopidine Stroke Prevention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Dr Chaturvedi has received honoraria in the past from Sanofi, Boehringer Ingelheim, Pfizer and Wyeth. Dr Chaturvedi also received a research grant from Pfizer. No other sources of funding were used in the preparation of this manuscript.


  1. 1.
    Feinberg WM, Albers GW, Barnett HJM, et al. Guidelines for the management of transient ischemic attacks. Stroke 1994; 25: 1320–35CrossRefGoogle Scholar
  2. 2.
    Levy DE. How transient are transient ischemic attacks? Neurology 1988; 38: 674–7PubMedCrossRefGoogle Scholar
  3. 3.
    Futty DE, Conneally M, Dyken ML, et al. Cooperative study of hospital frequency and character of transient ischemic attacks. V: symptom analysis. JAMA 1977; 238(22): 2386–90PubMedCrossRefGoogle Scholar
  4. 4.
    Kelly J, Hunt BJ, Lewis RR, et al. Transient ischemic attacks: under-reported, over-diagnosed, under-treated. Age Ageing 2001; 30: 379–81PubMedCrossRefGoogle Scholar
  5. 5.
    Rauch U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001; 134(3): 224–38PubMedGoogle Scholar
  6. 6.
    Albers GW, Hart RG, Lutsep HL, et al. AHA Scientific Statement: supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 1999; 30(11): 2502–11PubMedCrossRefGoogle Scholar
  7. 7.
    Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke. Stroke 2001; 32: 280–99PubMedCrossRefGoogle Scholar
  8. 8.
    Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757–64PubMedCrossRefGoogle Scholar
  9. 9.
    Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38PubMedCrossRefGoogle Scholar
  10. 10.
    Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38: UK Prospective Diabetes Study Group. BMJ 1998; 317(7160): 703–13CrossRefGoogle Scholar
  11. 11.
    Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989; 298: 789–94PubMedCrossRefGoogle Scholar
  12. 12.
    Wolf PA, D’Agostino RB, Kannel WB, et al. Cigarette smokingas a risk factor for stroke: the Framingham study. JAMA 1988; 259: 1025–9PubMedCrossRefGoogle Scholar
  13. 13.
    Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97CrossRefGoogle Scholar
  14. 14.
    Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin. Circulation 2001; 103: 387–92PubMedCrossRefGoogle Scholar
  15. 15.
    Reynolds K, Lewis LB, Nolen JDL, et al. Alcohol consumption and risk of stroke. JAMA 2003; 289: 579–88PubMedCrossRefGoogle Scholar
  16. 16.
    Albers GW. Atrial fibrillation and stroke. Arch Int Med 1994; 154: 1443–8CrossRefGoogle Scholar
  17. 17.
    Sacco RL, Ellenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989; 25(4): 382–90PubMedCrossRefGoogle Scholar
  18. 18.
    Markus HS, Ali N, Swaminathan R, et al. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997; 28(9): 1739–43PubMedCrossRefGoogle Scholar
  19. 19.
    Giles WH, Croft JB, Greenlund KJ, et al. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the Third National Health and Nutrition Examination Survey 1988–1994. Stroke 1998; 29(12): 2473–7PubMedCrossRefGoogle Scholar
  20. 20.
    Kidwell C, Saver JL. CT and MRI in transient ischemic attacks. In: Chaturvedi S, Levine SR, editors. Transient ischemic attacks. Boston (MA): Blackwell Science. In pressGoogle Scholar
  21. 21.
    Kidwell CS, Alger JR, Di Salle F, et al. Diffusion MRI in patients with transient ischemic attacks. Stroke 1999; 30(6): 1174–80PubMedCrossRefGoogle Scholar
  22. 22.
    Kittner SJ, Sharkness CM, Price TR, et al. Infarcts with a cardiac source of embolism in the NINCDS Stroke Data Bank: historical features. Neurology 1990; 40(2): 281–4PubMedCrossRefGoogle Scholar
  23. 23.
    Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318(18): 1148–52PubMedCrossRefGoogle Scholar
  24. 24.
    Di Tullio MR, Sacco RL, Homma S. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke: the French Study of Aortic Plaques in Stroke Group. N Engl J Med 1996; 334(19): 1216–21CrossRefGoogle Scholar
  25. 25.
    Swedish Aspirin Low-Dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events: the SALT Collaborative Group. Lancet 1991; 338(8779): 1345–9CrossRefGoogle Scholar
  26. 26.
    A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke: the Dutch transient ischaemic attack Trial Study Group. N Engl J Med 1991; 325(18): 1261–6CrossRefGoogle Scholar
  27. 27.
    Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial: ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353(9171): 2179–84PubMedCrossRefGoogle Scholar
  28. 28.
    Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143(1-2): 1–13PubMedCrossRefGoogle Scholar
  29. 29.
    Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321(8): 501–7PubMedCrossRefGoogle Scholar
  30. 30.
    Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; I(8649): 1215–20CrossRefGoogle Scholar
  31. 31.
    A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee. Lancet 1996; 348(9038): 1329–39CrossRefGoogle Scholar
  32. 32.
    Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345(20): 1444–51PubMedCrossRefGoogle Scholar
  33. 33.
    Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342(24): 1773–7PubMedCrossRefGoogle Scholar
  34. 34.
    Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494–502PubMedCrossRefGoogle Scholar
  35. 35.
    Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119(1 Suppl.): 300S–20SPubMedCrossRefGoogle Scholar
  36. 36.
    Hirsh JL, Dalen JE, Deykin D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108 Suppl.: 231S–46SPubMedCrossRefGoogle Scholar
  37. 37.
    Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342(8882): 1255–62PubMedGoogle Scholar
  38. 38.
    Homma S, Sacco RL, DiTullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale. Circulation 2002; 105: 2625–31PubMedCrossRefGoogle Scholar
  39. 39.
    A random trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin: The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997; 42: 857–65CrossRefGoogle Scholar
  40. 40.
    Chimowitz MI, Kokkinos J, Strong J, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995; 45(8): 1488–93PubMedCrossRefGoogle Scholar
  41. 41.
    Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19): 1349–57CrossRefGoogle Scholar
  42. 42.
    Cohn JN. ACE inhibition and vascular remodeling of resistance vessels: vascular compliance and cardiovascular implications. Heart Dis 2000; 2(2): S2–6PubMedGoogle Scholar
  43. 43.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53PubMedCrossRefGoogle Scholar
  44. 44.
    Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033–41CrossRefGoogle Scholar
  45. 45.
    Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345(17): 1243–9PubMedCrossRefGoogle Scholar
  46. 46.
    Wise PM, Dubal DB, Wilson ME, et al. Minireview: neuroprotective effects of estrogen-new insights into mechanisms of action. Endocrinology 2001; 142(3): 969–73PubMedCrossRefGoogle Scholar
  47. 47.
    MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis: European Carotid Surgery Trialists’ Collaborative Group. Lancet 1991; 337(8752): 235–43Google Scholar
  48. 48.
    Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis: Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 1991; 266(23): 3289–94PubMedCrossRefGoogle Scholar
  49. 49.
    Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis: North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325: 445–53CrossRefGoogle Scholar
  50. 50.
    Biller J, Feinberg WM, Castaldo JE, et al. Guidelines for carotid endarterectomy. Stroke 1998; 29: 554–62PubMedCrossRefGoogle Scholar
  51. 51.
    Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis: North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998; 339(20): 1415–25PubMedCrossRefGoogle Scholar
  52. 52.
    Goldstein LB, Moore WS, Robertson JT, et al. Complication rates for carotid endarterectomy: a call to action. Stroke 1997; 28(5): 889–90PubMedCrossRefGoogle Scholar
  53. 53.
    Chaturvedi S, Femino L. Are carotid endarterectomy complication rates being monitored? Neurology 1998; 50(6): 1927–8PubMedCrossRefGoogle Scholar
  54. 54.
    Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of transient ischaemic attack. JAMA 2000; 284(22): 2901–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Department of Neurology and Comprehensive Stroke ProgramWayne State University/Detroit Medical CenterDetroitUSA

Personalised recommendations